An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia (Q44202993)

30 November 2017

An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia (English)

1 reference

30 November 2017

0 references

cognitive dysfunction

1 reference

1

Robert W Buchanan

1 reference

30 November 2017

Ann Summerfelt

2

1 reference

30 November 2017

Cenk Tek

series ordinal

3

1 reference

30 November 2017

James Gold

series ordinal

4

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

30 November 2017

Schizophrenia Research

1 reference

30 November 2017

59

1 reference

30 November 2017

1

1 reference

30 November 2017

29-33

1 reference

Schizophrenia, sensory gating, and nicotinic receptors.

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900387-5

7 January 2021

The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900387-5

7 January 2021

Cholinesterase inhibitors: A new class of psychotropic compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900387-5

7 January 2021

Cholinergic enhancement and increased selectivity of perceptual processing during working memory.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900387-5

7 January 2021

Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Human recordings, computer simulation, and an animal model.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900387-5

7 January 2021

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900387-5

7 January 2021

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900387-5

7 January 2021

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900387-5

7 January 2021

Presynaptic nicotinic receptors facilitate monoaminergic transmission.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900387-5

7 January 2021

Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900387-5

7 January 2021

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900387-5

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900387-5

7 January 2021

Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2801%2900387-5

7 January 2021

10.1016/S0920-9964(01)00387-5

Identifiers

DOI

1 reference

30 November 2017

1 reference